Bayesian approaches to multiple sources of evidence and uncertainty in complex cost-effectiveness modelling

Statistics in Medicine

Volumn 22, Issue 23, 2003, Pages 3687-3709

  Spiegelhalter, David J ^a   Best, Nicola G ^b  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Deterministic sensitivity analysis; Evidence synthesis; Generalized meta analysis; Markov chain Monte Carlo simulation; Probabilistic sensitivity analysis; WinBUGS

Indexed keywords

ADULT; AGED; ARTICLE; BAYES THEOREM; COMPLEX FORMATION; COMPUTER PROGRAM; COMPUTER SIMULATION; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; FEMALE; HEALTH CARE POLICY; HIP PROSTHESIS; HUMAN; INTERMETHOD COMPARISON; MALE; MONTE CARLO METHOD; PROBABILITY; SENSITIVITY ANALYSIS; STATISTICAL MODEL; STATISTICAL PARAMETERS;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ARTHROPLASTY, REPLACEMENT, HIP; BAYES THEOREM; COST-BENEFIT ANALYSIS; FEMALE; HUMANS; MALE; MARKOV CHAINS; MIDDLE AGED; MODELS, ECONOMIC; PROSTHESES AND IMPLANTS; QUALITY OF LIFE; SEX FACTORS;

EID: 0344897785     PISSN: 02776715     EISSN: None     Source Type: Journal    
DOI: 10.1002/sim.1586     Document Type: Article

References (42)

1. Briggs AH. Handling uncertainty in cost-effectiveness models. Pharmacoeconomics 2000; 17:479-500.
2. Luce BR, Shih YCT, Claxton K. Bayesian approaches to technology assessment and decision making. International Journal of Technology Assessment in Health Care 2001; 17:1-5.
3. Manning WG, Fryback FG, Weinstein M. Reflecting uncertainty in cost-effectiveness analysis. In Cost Effectiveness in Health and Medicine, MR G, JR S, MC W, LB R (eds). Oxford University Press: New York, 1996; 247-275.
4. Spiegelhalter DJ, Thomas A, Best NG, Lunn D. WinBUGS Version 1.4 User Manual. MRC Biostatistics Unit, Cambridge, available from www.mrc-bsu.cam.ac.uk/bugs 2002.
5. Fryback DG, Stout NK, Rosenberg MA. An elementary introduction to Bayesian computing using WinBUGS. International Journal of Technology Assessment in Health Care 2001; 17:98-113.
6. Briggs AH, Gray AM. Methods in health service research - handling uncertainty in economic evaluations of healthcare interventions. British Medical Journal 1999; 319:635-638.
7. Burmaster DE, Wilson AM. An introduction to second-order random variables in human health risk assessments. Human Ecology Risk Assess 1996; 2:892-919.
8. Draper D. Assessment and propagation of model uncertainty. Journal of the Royal Statistical Society Series B 1995; 57:45-97.
9. Briggs A, Sculpher M. Markov models of medical prognosis - commentary. British Medical Journal 1997; 314:354-355.
10. Briggs A, Sculpher M. An introduction to Markov modelling for economic evaluation. Pharmacoeconomics 1998; 13:397-409.
11. Cronin KA, Legler JM, Etzioni RD. Assessing uncertainty in microsimulation modelling with application to cancer screening interventions. Statistics in Medicine 1998; 17(21):2509-2523.
12. NICE Appraisal Group. The effectiveness and cost effectiveness of different prostheses for primary total hip replacement. Technical Report, http://www.nice.org.uk 2000.
13. Fitzpatrick R, Shortall E, Sculpher M, Murray D, Morris R, Lodge M, et al. Primary total hip replacement surgery: a systematic review of outcomes and modelling cost effectiveness associated with different prostheses. Health Technoloqy Assessment 1998; 20(2):1-64.
14. Baxter K, Bevan G. An economic model to estimate the relative costs over 20 years of different hip prostheses. Journal of Epidemiology and Community Health 1999; 53:542-547.
15. Faulkner A, Kennedy LG, Baxter K, Donovan J, Wilkinson M, Bevan G. Effectiveness of hip prostheses in primary total hip replacement: a critical review of evidence and an economic model. Health Technology Assessment 1998; 20(6):1-133.
16. Malchau H, Herberts P, Ahnfelt L. Prognosis of total hip-replacement in Sweden - follow-up of 92,675 operations performed 1978-1990. Acta Orthopaedica Scandinavica 1993; 64:497-506.
17. Malchau H, Herberts P. Prognosis of total hip replacement: revision and re-revision rate in thr. a revision-risk study of 148,359 primary operations. In Proceedings of the 65th Annual Meeting of America Academy of Orthopaedic Surgeons, New Orleans, U.S.A., 1998.
18. Laupacis A, Bourne R, Rorabeck C, Feeny D, Wong C, Tugwell P, et al. The effect of elective total hip-replacement on health-related quality-of-life. Journal of Bone and Joint Surgery, American Volume 1993; 75A:1619-1626.
19. Palisade Europe. ®ISK 4.0. Technical Report, http://www.palisade-europe.com 2001.
20. Decisioneering. Crystal Ball. Technical Report, http://www.decisioneering.com/crystal_ball 2000.
21. Halpern EF, Weinstein MC, Hunink MGM, Gazelle GS. Representing both first- and second-order uncertainties by Monte Carlo simulation for groups of patients. Medical Decision Making 2000; 20:314-322.
22. O'Hagan A, Stevens JW, Montmartin J. Inference for the cost-effectiveness acceptability curve and cost-effectiveness ratio. Pharmacoeconomics 2000; 17:339-349.
23. O'Hagan A, Stevens JW. A framework for cost-effectiveness analysis from clinical trial data. Health Economics 2001; 10:303-315.
24. O'Hagan A, Stevens JW, Montmartin J. Bayesian cost-effectiveness analysis from clinical trial data. Statistics in Medicine 2001; 20:733-753.
25. Fryback DG, Chinnis JO, Ulvila JW. Bayesian cost-effectiveness analysis - an example using the gusto trial. International Journal of Technology Assessment in Health Care 2001; 17:83-97.
26. Smith TC, Spiegelhalter DJ, Thomas A. Bayesian graphical modelling applied to random effects meta-analysis. Statistics in Medicine 1995; 14:2685-2699.
27. Sutton A, Abrams KR, Jones DR, Sheldon TA, Song F. Methods for Meta-Analysis in Medical Research. Wiley: Chichester, 2000.
28. Droitcour J, Silberman G, Chelimsky E. Cross-design synthesis: a new form of meta-analysis for combining results from randomised clinical trials and medical-practice databases. International Journal of Technology Assessment in Health Care 1993; 9:440-449.
29. Eddy DM, Hasselblad V, Shachter R. Meta-Analysis by the Confidence Profile Method: the Statistical Synthesis of Evidence. Academic Press: San Diego, CA, 1992.
30. Prevost TC, Abrams KR, Jones DR. Hierarchical models in generalised synthesis of evidence: an example based on studies of breast cancer screening. Statistics in Medicine 2000; 19:3359-3376.
31. Larose DT, Dey DK. Grouped random effects models for Bayesian meta-analysis. Statistics in Medicine 1997; 16:1817-1829.
32. Dominici F, Parmigiani G, Wolpert R, Hasselblad V. Meta-analysis of migraine headache treatments: combining information from heterogeneous designs. Journal of American Statistical Association 1999; 94:16-28.
33. Marston RA, Cobb AG, Bentley G. Stanmore compared with Charnley total hip replacement - a prospective study of 413 arthroplasties. Journal of Bone and Joint Surgery British Volume 1996; 78B:178-184.
34. Britton AR, Murray DW, Bulstrode CJ, McPherson K, Denham RA. Long-term comparison of Charnley and Stanmore design total hip replacements. Journal of Bone and Joint Surgery British Volume 1996; 78B: 802-808.
35. Chessa AG, Dekker R, van Vliet B, Steyerberg EW, Habbema JDF. Correlations in uncertainty analysis for medical decision making: an application to heart-valve replacement. Medical Decision Making 1999; 19: 276-286.
36. Grieve AP. Issues for statisticians in pharmaco-economic evaluations. Statistics in Medicine 1998; 17: 1715-1723.
37. Heitjan DF, Moskowitz AJ, Whang W. Bayesian estimation of cost-effectiveness ratios from clinical trials. Health Economics 1999; 8:191-201.
38. Sendi PP, Craig BA, Meier G, Pfluger D, Gafni A, Opravil M, et al. Cost-effectiveness of azithromycin for preventing Mycobacterium avium complex infection in HIV-positive patients in the era of highly active antiretroviral therapy. Journal of Antimicrobial and Chemotherapy 1999; 44:811-817.
39. Briggs AH. A Bayesian approach to stochastic cost-effectiveness analysis - an illustration and application to blood pressure control in type 2 diabetes. International Journal of Technology Assessment in Health Care 2001; 17:69-82.
40. Claxton K. Bayesian approaches to the value of information: implications for the regulation of new pharmaceutical. Health Economics 1999; 8:269-274.
41. Russell LB. Modelling for cost-effectiveness analysis. Statistics in Medicine 1999; 18:3235-3244.
42. Sculpher M, Fenwick E, Claxton K. Assessing quality in decision analytic cost-effectiveness models- a suggested framework and example of application. Pharmacoeconomics 2000; 17:461-477.